Network Insights Methodology Get Access

Merck

ORG Health Care / Pharmaceuticals Momentum 15.2ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$60B+ revenue (2025), Rahway-based Merck slashed Zepatier hepatitis C drug pricing this week while advancing sac-TMT antibody-drug conjugate through Phase 3 trials ahead of schedule. Core oncology and infectious disease franchises drive 60%+ of pharmaceutical sales.

Price reduction strategy on Zepatier (hepatitis C treatment) to maintain market competitiveness; sac-TMT (antibody-drug conjugate) Phase 3 trial success positions pipeline advancement.
0.01
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
15.2
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
7
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Merck is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Connected Entities
Pfizer Novartis China Sanofi AstraZeneca European Union Eli Lilly India Bay Area FDA EPA
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-25 2026-05-25 7 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.550
Narrative Drift
0.000
Spectral Shift
624.046
Sentiment-Momentum Divergence
0.000
Source Concentration
0.973
Signal
Merck is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Driver
Ranked #5 of 6 in Health Care — in line with sector peers. PSI stable vs yesterday (-1.00). Confidence: 63% (entity has limited history, score is shrunk toward sector prior).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
5 of 6
Sector Rank
+0.00
Peer Z-Score
20%
Sector Percentile
Network Analysis
7 Degree Centrality
Ego Network (top connections)
Pfizer (weight 70.0)Novartis (weight 68.0)China (weight 7.0)Sanofi (weight 4.0)AstraZeneca (weight 3.0)European Union (weight 2.0)Eli Lilly (weight 2.0)India (weight 2.0) PfizerNovartisChinaSanofiAstraZenecaEuropean UnionEli LillyIndia Merck (degree 7) Merck
Centrality History
2026-04-25 2026-05-25 7 0 Degree Mentions
EntityWeight StatusFirst Seen
Pfizer 70 STRENGTHENED
Novartis 68 STRENGTHENED
China 7 STABLE
Sanofi 4 NEW
AstraZeneca 3 NEW
European Union 2 STABLE
Eli Lilly 2 NEW
India 2 STABLE
Bay Area 2 NEW
FDA 2 STABLE
EPA 1 STABLE
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-25 ← Intelligence Network